- Home
- DFH vs GLPG Comparison
DFH vs GLPG Comparison
Compare DFH & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFH
- GLPG
- Stock Information
- Founded
- DFH 2008
- GLPG 1999
- Country
- DFH United States
- GLPG Belgium
- Employees
- DFH N/A
- GLPG N/A
- Industry
- DFH Homebuilding
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- DFH Consumer Discretionary
- GLPG Health Care
- Exchange
- DFH Nasdaq
- GLPG Nasdaq
- Market Cap
- DFH 2.2B
- GLPG 2.1B
- IPO Year
- DFH 2021
- GLPG 2005
- Fundamental
- Price
- DFH $23.30
- GLPG $31.95
- Analyst Decision
- DFH Hold
- GLPG Hold
- Analyst Count
- DFH 1
- GLPG 4
- Target Price
- DFH $26.00
- GLPG $30.00
- AVG Volume (30 Days)
- DFH 292.4K
- GLPG 285.3K
- Earning Date
- DFH 10-31-2025
- GLPG 11-05-2025
- Dividend Yield
- DFH N/A
- GLPG N/A
- EPS Growth
- DFH 0.34
- GLPG N/A
- EPS
- DFH 3.08
- GLPG N/A
- Revenue
- DFH $4,708,435,000.00
- GLPG $323,674,692.00
- Revenue This Year
- DFH $6.07
- GLPG $1.77
- Revenue Next Year
- DFH $1.25
- GLPG $0.44
- P/E Ratio
- DFH $7.54
- GLPG N/A
- Revenue Growth
- DFH 20.19
- GLPG 5.43
- 52 Week Low
- DFH $19.65
- GLPG $22.36
- 52 Week High
- DFH $34.43
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- DFH 39.28
- GLPG 41.51
- Support Level
- DFH $22.80
- GLPG $31.06
- Resistance Level
- DFH $23.67
- GLPG $32.62
- Average True Range (ATR)
- DFH 0.90
- GLPG 0.81
- MACD
- DFH -0.00
- GLPG -0.39
- Stochastic Oscillator
- DFH 37.05
- GLPG 21.80
About DFH Dream Finders Homes Inc.
Dream Finders Homes Inc is engaged in the home building business. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the majority of its revenue from the Midwest segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.